1940s~
The world’s first company to successfully
produce chondroitin sulfate on a commercial scale.
1947
Kosei Suisan K.K. established in Minato-ku, Tokyo.
Kurihama Plant opens in Kanagawa.
1950
Industrial production of chondroitin sulfate as a pharmaceutical begins.
1952
Head Office relocated to Chuo-ku, Tokyo.
1953
Name of company changed to K.K. Seikagaku Kenkyusho.
1960
Tokyo Research Institute opens in Shinjuku-ku, Tokyo.
Development and marketing of research biochemicals begins.
1962
Name of company changed to Seikagaku Corporation.
1968
Tokyo Research Institute relocated to Higashiyamato-shi, Tokyo.
1970s~
Pharmaceuticals using hyaluronic acid are developed.
1975
Takahagi Plant opens in Ibaraki.
1981
World's first endotoxin colorimetry reagent developed and manufactured.
1987
Marketing begins for hyaluronic acid formulations ARTZ and OPEGAN.
1989
Company stock registered with the Japan Securities Dealers Association.
1990s~
Enhances its range of pharmaceuticals using hyaluronic acid
and expands its activities in overseas markets.
1992
Overseas marketing of ARTZ begins (Sweden).
1993
Marketing begins for ARTZ Dispo, a new formulation.
1997
Acquisition of Associates of Cape Cod, Inc. (U.S.A.)
1998
Quality Management System certification ISO 9001/EN 46001, ISO 13485 obtained (superseded by ISO 13485 certification since 2010).
2000
Name of Tokyo Research Institute changed to Central Research Laboratory.
2001
Marketing begins for hyaluronic acid formulation SUPARTZ in U.S.A.
2004
Listing moved to the Tokyo Stock Exchange, Second Section.
2005
Listing moved to the Tokyo Stock Exchange, First Section.
Head Office relocated to Chiyoda-ku, Tokyo.
2007
Marketing begins for a hyaluronic acid medical device MucoUp.
Seikagaku Biobusiness Corporation established.
2012
Marketing begins for a single injection hyaluronic acid formulation Gel-One in U.S.A.
Absorption-type Merger of Seikagaku Biobusiness Corporation.
2013
CMC Laboratory established.
2016
Marketing begins for SHELLGAN 0.5 Ophthalmic viscoelastic devices for the ophthalmic surgcal aid in Japan.
2018~
Reaches a new stage with the launch of a treatment agent
for lumbar disc herniation.
2018
Marketing begins for HERNICORE 1.25 Units for Intradiscal Injection in Japan.
2019
Marketing begins for HyLink Intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy.
2020
Acquisition of Dalton Chemical Laboratories, Inc. (Canada).
2021
Marketing begins for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint) in Japan.
2021
Marketing begins for HyLink Intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan.
2022
Listing moved to the Tokyo Stock Exchange, Prime Market.